Silvia de Muga

640 total citations
15 papers, 479 citations indexed

About

Silvia de Muga is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Silvia de Muga has authored 15 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Silvia de Muga's work include Prostate Cancer Treatment and Research (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Silvia de Muga is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Silvia de Muga collaborates with scholars based in Spain, United States and Germany. Silvia de Muga's co-authors include Josep Lloreta, Sílvia Hernández, José A. Lorente, Sérgio Serrano, Laia Agell, Marta Lorenzo, Núria Juanpere, Marta Salido, Raquel Esgueva and Sergi Mojal and has published in prestigious journals such as PLoS ONE, American Journal Of Pathology and Annals of Oncology.

In The Last Decade

Silvia de Muga

15 papers receiving 469 citations

Peers

Silvia de Muga

PRM

SURGE

ONCOL

Gian Luca Rampioni Vinciguerra Italy

Nina Waldburger Germany

Matthew R. Strickland United States

Karen Petersen Germany

Esther Sanfeliu Spain

Asha Padar United States

Jung-Ah Hwang South Korea

Theresia Wilbertz Switzerland

Christine G. Hammerschmied Germany

Christian Vay Germany

Gian Luca Rampioni Vinciguerra Italy

Silvia de Muga

238 ×0.9

134 ×0.7

PRM

107 ×0.7

58 ×0.5

SURGE

181 ×1.6

ONCOL

Citations per year, relative to Silvia de Muga Silvia de Muga (= 1×) peers Gian Luca Rampioni Vinciguerra

Countries citing papers authored by Silvia de Muga

Since Specialization

Citations

This map shows the geographic impact of Silvia de Muga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia de Muga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia de Muga more than expected).

Fields of papers citing papers by Silvia de Muga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia de Muga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia de Muga. The network helps show where Silvia de Muga may publish in the future.

Co-authorship network of co-authors of Silvia de Muga

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia de Muga. A scholar is included among the top collaborators of Silvia de Muga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia de Muga. Silvia de Muga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Martínez, Roberto, Gustavo Tapia, Silvia de Muga, et al.. (2019). Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. OncoImmunology. 8(8). 1602460–1602460. 27 indexed citations

Lloreta, Josep, Alba Font‐Tello, Núria Juanpere, et al.. (2017). FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. Human Pathology. 62. 222–231. 17 indexed citations

Juanpere, Núria, Silvia de Muga, Marta Lorenzo, et al.. (2017). ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. Oncotarget. 8(43). 74106–74118. 16 indexed citations

Hernández, Sílvia, Alba Font‐Tello, Núria Juanpere, et al.. (2016). ConcurrentTMPRSS2-ERGandSLC45A3-ERGrearrangements plusPTENloss are not found in low grade prostate cancer and define an aggressive tumor subset. The Prostate. 76(9). 854–865. 16 indexed citations

Bellmunt, Joaquim, Lillian Werner, Aristotle Bamias, et al.. (2015). HER2 as a target in invasive urothelial carcinoma. Cancer Medicine. 4(6). 844–852. 43 indexed citations

Font‐Tello, Alba, Núria Juanpere, Silvia de Muga, et al.. (2015). Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. The Prostate. 75(11). 1216–1226. 53 indexed citations

Clavé, Sergi, Javier Gimeno, Silvia de Muga, et al.. (2014). Ros1 Rearrangements and Copy Number Alterations in Nsclc Patients: High Frequency of Ros1 Deletions. Annals of Oncology. 25. iv566–iv566. 1 indexed citations

Bellmunt, Joaquim, Shamini Selvarajah, Scott J. Rodig, et al.. (2014). Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE. 9(8). e103325–e103325. 11 indexed citations

Muga, Silvia de, Sílvia Hernández, Marta Salido, et al.. (2013). CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement. Cancer Biomarkers. 12(1). 21–30. 11 indexed citations

10.

Agell, Laia, Sílvia Hernández, Lara Nonell, et al.. (2012). A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer. American Journal Of Pathology. 181(5). 1585–1594. 40 indexed citations

11.

Juanpere, Núria, Laia Agell, Marta Lorenzo, et al.. (2012). Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Human Pathology. 43(10). 1573–1582. 48 indexed citations

12.

Muga, Silvia de, Sílvia Hernández, Laia Agell, et al.. (2010). Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Modern Pathology. 23(5). 703–712. 54 indexed citations

13.

Agell, Laia, Sílvia Hernández, Marta Salido, et al.. (2010). PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Modern Pathology. 24(3). 443–452. 41 indexed citations

14.

Hernández, Sílvia, Silvia de Muga, Laia Agell, et al.. (2009). FGFR3 mutations in prostate cancer: association with low-grade tumors. Modern Pathology. 22(6). 848–856. 61 indexed citations

15.

Agell, Laia, Sílvia Hernández, Silvia de Muga, et al.. (2008). KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Modern Pathology. 21(12). 1470–1478. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact